Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $23.59, but opened at $24.87. LENZ Therapeutics shares last traded at $24.62, with a volume of 43,582 shares traded.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on LENZ shares. TD Cowen assumed coverage on shares of LENZ Therapeutics in a research note on Tuesday. They set a "buy" rating and a $60.00 price target on the stock. Citigroup boosted their price objective on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $41.67.
Read Our Latest Research Report on LENZ
LENZ Therapeutics Stock Up 0.7 %
The stock's 50 day moving average price is $24.15 and its two-hundred day moving average price is $27.06. The stock has a market cap of $728.50 million, a price-to-earnings ratio of -5.55 and a beta of 0.58.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of LENZ Therapeutics during the 4th quarter worth approximately $29,000. SG Americas Securities LLC increased its holdings in LENZ Therapeutics by 20.7% in the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock valued at $158,000 after buying an additional 935 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in LENZ Therapeutics by 14.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company's stock valued at $229,000 after buying an additional 1,005 shares in the last quarter. Rhumbline Advisers raised its position in shares of LENZ Therapeutics by 6.2% in the fourth quarter. Rhumbline Advisers now owns 18,754 shares of the company's stock worth $541,000 after acquiring an additional 1,100 shares during the period. Finally, Tower Research Capital LLC TRC boosted its stake in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after acquiring an additional 1,151 shares in the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
See Also
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
